Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
Phase II, single-centre, open label, two parallel arm cohort randomised controlled trial
(RCT) testing abatacept in a population of anti-CCP Ab positive individuals at moderate to
high risk of developing IA according to a published risk score, already followed in the
observational study 'CCP: Next Generation'